Know Cancer

or
forgot password

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors


Phase 1
18 Years
N/A
Open (Enrolling)
Both
Solid Tumor Cancer

Thank you

Trial Information

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors


Inclusion Criteria:



- Histologically confirmed solid tumor which is metastatic or unresectable with no
known effective treatment measures,

- ECOG performance status of
- Adequate bone marrow reserve, hepatic, renal, and cardiovascular function,

- Negative pregnancy test.

Exclusion Criteria:

- Chemotherapy within 4-6 weeks of the start of treatment,

- Radiotherapy within 4 weeks of the start of treatment,

- Known brain metastasis,

- Uncontrolled medical disorder such as infection or cardiovascular disease,

- HIV positive,

- Pregnant or breastfeeding women

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the maximum tolerated dose (MTD) and toassess the safety and tolerability of GSK1363089 administered orally (up to twelve different doses) to subjects with solid tumors

Outcome Time Frame:

3 years

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

United States: Food and Drug Administration

Study ID:

MET111647

NCT ID:

NCT00742131

Start Date:

March 2005

Completion Date:

October 2009

Related Keywords:

  • Solid Tumor Cancer
  • Solid Tumors
  • GSK1363089
  • XL880
  • MET inhibitor
  • c-Met
  • Neoplasms

Name

Location